Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus.

Frew JW, Martin LK, Murrell DF.

Dermatol Clin. 2011 Oct;29(4):599-606. doi: 10.1016/j.det.2011.07.001. Review.

PMID:
21925004
2.

Diagnosis and clinical features of pemphigus vulgaris.

Venugopal SS, Murrell DF.

Immunol Allergy Clin North Am. 2012 May;32(2):233-43, v-vi. doi: 10.1016/j.iac.2012.04.003. Review.

PMID:
22560136
3.

Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review.

Singh S.

Indian J Dermatol Venereol Leprol. 2011 Jul-Aug;77(4):456-69. doi: 10.4103/0378-6323.82400. Review.

4.

A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.

Martin LK, Werth VP, Villaneuva EV, Murrell DF.

J Am Acad Dermatol. 2011 May;64(5):903-8. doi: 10.1016/j.jaad.2010.04.039. Epub 2011 Feb 25. Review.

PMID:
21353333
5.

Oxidative stress index may play a key role in patients with pemphigus vulgaris.

Yesilova Y, Ucmak D, Selek S, Dertlioğlu SB, Sula B, Bozkus F, Turan E.

J Eur Acad Dermatol Venereol. 2013 Apr;27(4):465-7. doi: 10.1111/j.1468-3083.2012.04463.x. Epub 2012 Feb 10.

PMID:
22324759
6.

Treatment of pemphigus vulgaris: current and emerging options.

Yeh SW, Sami N, Ahmed RA.

Am J Clin Dermatol. 2005;6(5):327-42. Review.

PMID:
16252932
7.

Urban legends: pemphigus vulgaris.

Cirillo N, Cozzani E, Carrozzo M, Grando SA.

Oral Dis. 2012 Jul;18(5):442-58. doi: 10.1111/j.1601-0825.2011.01899.x. Epub 2012 Feb 15. Review. Erratum in: Oral Dis. 2012 Sep;18(6):624.

PMID:
22335787
8.

Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.

Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ.

J Invest Dermatol. 2010 Aug;130(8):2041-8. doi: 10.1038/jid.2010.91. Epub 2010 Apr 22.

9.

Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice.

Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, Iwakura Y, Yoshimura A, Yamada T, Kuwana M, Fujii H, Koyasu S, Amagai M.

J Clin Invest. 2011 Sep;121(9):3677-88. doi: 10.1172/JCI57379. Epub 2011 Aug 8.

10.

Diagnosis and clinical features of pemphigus vulgaris.

Venugopal SS, Murrell DF.

Dermatol Clin. 2011 Jul;29(3):373-80, vii. doi: 10.1016/j.det.2011.03.004. Review.

PMID:
21605802
11.

Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.

Femiano F.

Minerva Stomatol. 2007 Apr;56(4):215-23. Review. English, Italian.

12.

Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris.

Gil MP, Modol T, España A, López-Zabalza MJ.

Exp Dermatol. 2012 Apr;21(4):254-9. doi: 10.1111/j.1600-0625.2012.01441.x. Epub 2012 Feb 10.

PMID:
22320676
13.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

14.

Uric Acid: a new antioxidant in patients with pemphigus vulgaris.

Yousefi M, Rahimi H, Barikbin B, Toossi P, Lotfi S, Hedayati M, Younespour S.

Indian J Dermatol. 2011 May;56(3):278-81. doi: 10.4103/0019-5154.82480.

15.

Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris.

Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, Barzilai A.

Eur J Dermatol. 2012 Jan-Feb;22(1):83-7. doi: 10.1684/ejd.2011.1611.

PMID:
22266247
16.

Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris.

Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, Israeli S, Sagiv N, Martinez de Morentin H, Katz O, Baum S, Barzilai A, Trau H, Murrell DF, Bergman R, Hertl M, Rosenberg S, Nöthen MM, Skorecki K, Schmidt E, Zillikens D, Darvasi A, Geiger D, Rosset S, Ibrahim SM, Sprecher E.

J Invest Dermatol. 2012 Jul;132(7):1798-805. doi: 10.1038/jid.2012.46. Epub 2012 Mar 22.

17.

Neonatal pemphigus in an infant born to a mother with serologic evidence of both pemphigus vulgaris and gestational pemphigoid.

Panko J, Florell SR, Hadley J, Zone J, Leiferman K, Vanderhooft S.

J Am Acad Dermatol. 2009 Jun;60(6):1057-62. doi: 10.1016/j.jaad.2008.10.025.

PMID:
19467379
18.

The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic.

Ding X, Diaz LA, Fairley JA, Giudice GJ, Liu Z.

J Invest Dermatol. 1999 May;112(5):739-43.

19.

Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris.

Zhao M, Huang W, Zhang Q, Gao F, Wang L, Zhang G, Su Y, Xiao R, Zhang J, Tang M, Cheng W, Tan Y, Lu Q.

Br J Dermatol. 2012 Sep;167(3):523-31. doi: 10.1111/j.1365-2133.2012.11007.x. Epub 2012 Aug 10.

PMID:
22512277
20.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407

Supplemental Content

Support Center